Shares of rare-disease drugmaker Amicus Therapeutics (NASDAQ: FOLD) shed 20% of their value in August, according to data from S&P Global Market Intelligence. And what caused investors to head for the exits last month? Apparently, a question.
On Aug. 8, Amicus released its second-quarter earnings report. During the conference call that followed, Bank of America analyst Tazeen Ahmad noted that rival Sanofi's (NASDAQ: SNY) ongoing Phase 3 Pompe disease study for neoGAA should read out ahead of Amicus' late-stage Pompe trial for AT-GAA. The analyst also questioned whether the neoGAA study's lung function primary endpoint might be viewed more favorably among caregivers than AT-GAA's 6-minute walk test.
Image Source: Getty Images.
The stock's nosedive following this line of questioning by Ahmad is a testament to just how nervous the market is about Amicus's competitive position in Pompe disease. It's not exactly breaking news that Sanofi's neoGAA program will deliver its data almost a year ahead of AT-GAA's pivotal trial, after all. What's important to keep in mind is that Amicus is aiming to develop AT-GAA into the gold standard for Pompe disease. As such, the therapy's efficacy and safety results will be paramount -- not how quickly they are released.
Should investors take advantage of this dip? While Amicus' shares now trade well below their 52-week high, the biotech's stock valuation remains in nosebleed territory at more than 20 times the company's trailing 12-month sales. That's one of the richest valuations in the entire healthcare sector at the moment. So while it may seem like this double-digit percentage selloff has provided investors with an attractive entry point, it might be a good idea to take a cautious approach with this rare-disease stock for the time being.
10 stocks we like better than Amicus Therapeutics
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Amicus Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.
*Stock Advisor returns as of June 1, 2019
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.